01.06.2004 | Report
Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial
Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2004
Einloggen, um Zugang zu erhalten